You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾(06185.HK):暫不加入HPV疫苗競爭 不會過度開發已有疫苗
康希諾生物(06185.HK)首席科學官朱濤表示,市場上現有的二價及九價HPV疫苗,無論在酵母,抑或蟲細胞的疫苗技術路線效果均很好,相關技術需要再提高亦十分困難。因此康希諾生物在現時暫不打算加入HPV疫苗競爭。 「新質生產力」是今年兩會期間的熱詞。朱濤認為,新質生產力就是高科技、高效能的生產力,放在疫苗行業就是建議不要再去過度開發已有品類的仿製疫苗。對於康希諾來說,如果一款疫苗不能在安全性和有效性上對現有疫苗進行提高,就不會選擇去做。 另外他亦提到,現時國產疫苗出口到海外,部分國家支持雙語標籤,而中國在現階段仍只支持中文標簽。以上情況導致貼了外文標籤的疫苗無辦法在中國銷售,有時候訂單亦不能夠預測得十分準確,在這個情況下以外文包裝的產品便有機會報廢。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account